Navigation Links
ENCO Pharmaceutical Development Announces Another Successful FDA Inspection - Its 2nd This Year
Date:3/20/2013

JACKSONVILLE, Fla., March 20, 2013 /PRNewswire-iReach/ --  ENCO Pharmaceutical Development's Jacksonville, FL Facility Completes Successful FDA Audit

ENCO Pharmaceutical Development, Inc. (EPDI) is pleased to announce the completion of a successful FDA inspection of its Jacksonville FL facility.  The audit was a directed Pre-approval Inspection (PAI). 

The audit occurred between March 7th and 8th, 2013.  Upon the completion of the inspection, the investigator reported no findings and no Form 483 was issued.

"As a company we understand the value of maintaining a high level of compliance," said Mark Inman , Ph.D., VP and Director of Quality Assurance.  "Not only do we want to ensure adherence to the existing regulatory requirements, EPDI also remains connected to the various regulatory bodies we work with to keep the company at the forefront of changes in the regulatory industry."

This audit marks the second consecutive month that an EPDI facility has been audited by the FDA.  In February, auditors inspected EPDI's Cary, NC facility.  "Between the two audits, our company has experienced nearly 5 days of intensive inspection by the FDA with no 483's or observations to report," Mark Inman continued. 

The audit covered thorough reviews of general systems such as training, equipment calibration/qualification, SOP's, protocols and methods and involved a variety of technical areas including analytical development and release testing.

ENCO Pharmaceutical Development Inc. provides a broad spectrum of pharmaceutical development and analytical services from its facilities in Jacksonville, FL and Cary, NC.  The company works with a variety of organizations in both the pharmaceutical and medical device industries, including global, small and mid-size firms, as well as virtual organizations. EPDI provides expertise in formulation development of solid, semi-solid, liquids, ophthalmic and lyophilized dosage forms as well as analytical support for method development and validation, stability studies, raw materials testing, extractable/leachable studies, medical device testing and more. For additional information, please visit www.encopharma.com.

Media Contact: Keith Hurley , ENCO Pharmaceutical Development, Inc., 336.541.3270, khurley@encopharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ENCO Pharmaceutical Development, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 Global ... drainage devices are tubes used to remove excess liquid ... blood, serum, pus, urine, bile or lymph. Surgical drains ... of surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, ... is prophylactic post-surgery to prevent accumulation of fluid e.g. ...
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence that ... Parkinson,s, according to a study released today that will be ... Meeting in Boston , April 22 ... the treatment of Parkinson,s disease, the oral drug levodopa has ... and longevity. But as the disease progresses, the effects of ...
Breaking Medicine Technology:
(Date:4/26/2017)... DC (PRWEB) , ... April ... ... Association (ATA) is thrilled to announce the ATA 2017 President’s Awards recipients, ... innovation and demonstrated superior healthcare delivery. , The ATA 2017 President’s ...
(Date:4/26/2017)... ... 2017 , ... Elisabete Miranda, president and CEO of ... magazine as one of its 2017 Enterprising Women of the Year, a prestigious ... that they have fast-growth businesses, mentor or actively support other women and girls ...
(Date:4/26/2017)... Miami, FL (PRWEB) , ... April 26, 2017 , ... ... twenty-fifth anniversary as a dentist. , “I could have never imagined back in 1991 ... and personally,” said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... specifically to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers ... alternative to dairy proteins, providing direct cost savings as well as more stable ...
(Date:4/25/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically ... aging, and minimize the appearance of pores – all with minimal downtime and ...
Breaking Medicine News(10 mins):